Repare stock soars after Montreal cancer drug developer strikes US$1-billion-plus deal with Roche
2022 The Globe and Mail Inc.
business
2022-06-02 10:29:14

Shares in Montreal cancer drug developer Repare Therapeutics Inc. RPTX-Q soared Friday morning after the company announced a deal with pharmaceutical giant F. Hoffman-La Roche AG that could be worth north of US$1-billion to the Canadian startup.Repare's share price increased by 34 per cent in early trading on the Nasdaq exchange after the company revealed late Thursday it had entered into a worldwide license and collaboration agreement with Roche to develop and commercialize the Montreal company's drug camonsertib, also known as RP-3500.
